We are live on ! Find out more
BIVV

Bioverativ Inc. Common Stock
BIVV

Delisted

BIVV was delisted on the 8th of March, 2018.

Back to rankings

459 hedge funds and large institutions have $5.76B invested in Bioverativ Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 79 funds opening new positions, 127 increasing their positions, 175 reducing their positions, and 64 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 3 → 5 (+2)

23% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 64

3% more funds holding

Funds holding: 446 → 459 (+13)

6% more call options, than puts

Call options by funds: $16.8M | Put options by funds: $15.8M

2% less capital invested

Capital invested by funds: $5.89B → $5.76B (-$135M)

27% less repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 175

Holders
459
Holders Change
+13
Holders Change %
+2.91%
% of All Funds
10.41%
Holding in Top 10
5
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+66.67%
% of All Funds
0.11%
New
79
Increased
127
Reduced
175
Closed
64
Calls
$16.8M
Puts
$15.8M
Net Calls
+$946K
Net Calls Change
+$9.24M

Top Buyers

Rank Fund Capital Flow
1
EIG
EdgePoint Investment Group
Ontario, Canada
+$177M
2
BlackRock
BlackRock
New York
+$85.8M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$71.2M
4
SCM
Sarissa Capital Management
Connecticut
+$63.7M
5
O
OppenheimerFunds
New York
+$46.7M

Top Sellers

Rank Fund Capital Flow
1
VH
ValueAct Holdings
California
-$72.5M
2
Goldman Sachs
Goldman Sachs
New York
-$63.3M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$58.1M
4
Jennison Associates
Jennison Associates
New York
-$56.4M
5
FCM
Frontier Capital Management
Massachusetts
-$46.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFO
401
Pathstone Family Office
New Jersey
$4K +$4.54K +83 New
GFP
402
Gryphon Financial Partners
Ohio
$4K +$4.76K +87 New
GBBWRPM
403
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$3K -$109 -2 -9%
GWS
404
Glassman Wealth Services
Virginia
$3K -$109 -2 -4%
BFEC
405
Benjamin F. Edwards & Company
Missouri
$3K – – –
DAM
406
Delta Asset Management
Tennessee
$3K – – –
DSN
407
D. Scott Neal
Kentucky
$3K – – –
HFM
408
Hartford Financial Management
Connecticut
$3K – – –
PS
409
Portfolio Solutions
Michigan
$3K – – –
SNT
410
Security National Trust
West Virginia
$3K – – –
SIAS
411
Shine Investment Advisory Services
Colorado
$3K – – –
TFO
412
Tarbox Family Office
California
$3K – – –
SBL
413
Sargent Bickham Lagudis
Colorado
$3K +$2.02K +37 +370%
VFA
414
Valeo Financial Advisors
Indiana
$3K +$2.08K +38 +380%
WOC
415
West Oak Capital
California
$2.32K – – –
ST
416
Smithfield Trust
Pennsylvania
$2K -$50.1K -916 -95%
LNB
417
Ledyard National Bank
$2K -$1.64K -30 -51%
CAW
418
Cornerstone Advisors (Washington)
Washington
$2K -$821 -15 -31%
AF
419
Arrow Financial
New York
$2K – – –
BWA
420
Burt Wealth Advisors
Maryland
$2K – – –
CCM
421
Covington Capital Management
California
$2K – – –
CCM
422
Cribstone Capital Management
Maine
$2K – – –
HI
423
Hudock Inc
Pennsylvania
$2K – – –
PCFFS
424
Pacific Center for Financial Services
California
$2K – – –
VNA
425
Valley National Advisers
Pennsylvania
$2K – – –
15 16
17
18 19

BIVV Hedge Fund Activity: Q4 2017 in Review

459 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q4 2017, worth a combined $5.76B — down 2.3% from $5.89B a quarter earlier.

Buyers outnumbered sellers: 79 funds opened new BIVV positions and 64 closed out — a net gain of 15 holders — while 127 added to existing stakes and 175 trimmed.

The largest buyer was EdgePoint Investment Group, opening a new position worth an estimated $177M. The largest seller was ValueAct Holdings, exiting entirely with an estimated $72.5M sold.

  • 459 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q4 2017, up from 446 in Q3 2017.
  • Funds reported $5.76B of Bioverativ Inc. Common Stock stock for Q4 2017, down 2.3% quarter-over-quarter.
  • 79 funds opened new Bioverativ Inc. Common Stock positions in Q4 2017 and 64 closed out, a net change of +15 holders.
  • The largest Bioverativ Inc. Common Stock buyer in Q4 2017 was EdgePoint Investment Group, an estimated $177M added.
  • The largest Bioverativ Inc. Common Stock seller in Q4 2017 was ValueAct Holdings, an estimated $72.5M sold.

Based on aggregated 13F filings for Q4 2017.